Stockreport

Nektar Therapeutics: Cautiously Positive Moving Into Phase 2b Readout [Seeking Alpha]

Nektar Therapeutics  (NKTR) 
Last nektar therapeutics earnings: 2/27 04:15 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.nektar.com/investor-relations
PDF NKTR's value now centers on Treg biology, advancing Rezpeg and NKTR-0165, and leveraging legacy oncology partnerships for monetization. Key catalysts are upcoming Q1 [Read more]